F9603 From diagnosis towards pharmaceutics

Faculty of Science
Autumn 2024
Extent and Intensity
2/1/0. 3 credit(s) (plus extra credits for completion). Type of Completion: z (credit).
Teacher(s)
doc. Mgr. Karel Kubíček, PhD. (lecturer)
doc. Mgr. Olga Nováková, Dr. (lecturer)
Guaranteed by
doc. Mgr. Karel Kubíček, PhD.
Department of Condensed Matter Physics – Physics Section – Faculty of Science
Contact Person: Mgr. Dušan Hemzal, Ph.D.
Supplier department: Department of Condensed Matter Physics – Physics Section – Faculty of Science
Prerequisites
Basic knowledge of human body, nucleic acids, proteins, organic chemistry and basic label knowledge of theoretical and experimental methods applied for studies of interactions between biomolecules
Course Enrolment Limitations
The course is also offered to the students of the fields other than those the course is directly associated with.
fields of study / plans the course is directly associated with
Course objectives
The goal of the course is to provide the students logical connections between the macro-/micro-scopic aspects of several common diseases of humans (Alzheimer, Bekhterev, cancer) and changes in protein primary to tertiary structure, which affect the protein-protein interaction, (un)folding of the protein, protein-nucleic acid interaction, protein-ligand interaction. The course will also show the strategies for designing cures and therapy of these diseases.
Learning outcomes
Upon completion of the course, the student will:
- understand the process and time requirements of disease diagnosis at the molecular level;
- be able to assess which experimental method is appropriate for obtaining what data on a given sample/tissue;
- to navigate the process of identifying and approving new drugs;
- understand the risks and costs of bringing a new drug from discovery to market;
- be able to assess the difference between a new drug in silico and its final form in vivo;
- be able to use appropriate in silico tools for drug design;
- be familiar with tumour types, their study and the use of e.g. cisplatin derivatives for anti-cancer therapy;
Syllabus
  • 1) The concept of identification and characterization of a disease 2) Historical evolution of therapy 3) Identification of a disease at a molecular level 4) The role of (un)folding, changes in primary sequence 5) Protein-protein, protein-NA, protein-ligand interactions 6) Drug-design
Literature
    recommended literature
  • Fillit, H.M. & O'Connell, A.W.: DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE 2000, Springer, 2002
  • Factor, S.A. & Weiner, W.J.: Parkinson’s Disease Diagnosis and Clinical Management 2nd Ed, Demos, NY, 2008
  • Hobbie, R.K. & Roth, B.J.: Intermediate Physics for Medicine and Biology 4th Ed, Springer, 2007
  • Jucker, M., Beyreuther, K., Haass, C., Nitsch, R.M., Christen, Y.:)Alzheimer:100 Years and Beyond, Springer, 2006
Teaching methods
lectures, class discussion
Assessment methods
Final oral exam – dissection of scientific publication
Language of instruction
Czech
Further Comments
The course is taught annually.
The course is also listed under the following terms Autumn 2011, Autumn 2011 - acreditation, spring 2012 - acreditation, Autumn 2012, Autumn 2013, Autumn 2014, Autumn 2015, Autumn 2016, autumn 2017, Autumn 2018, Autumn 2019, Autumn 2020, autumn 2021, Autumn 2022, Autumn 2023.
  • Enrolment Statistics (recent)
  • Permalink: https://is.muni.cz/course/sci/autumn2024/F9603